BST-106

BST-106 is a preclinical-stage small molecule cannabinoid derivative under development by Blackstone Therapeutics. It is primarily being investigated for its anti-tumor activity against solid malignancies, with a focus on pancreatic cancer and lung cancer. While the specific molecular mechanism of action and biological targets have not been publicly disclosed by the developer, the compound is part of a platform leveraging cannabinoid-based chemistry to address high-unmet-need oncological indications. Preclinical studies are focused on evaluating its efficacy in inhibiting tumor growth and progression in difficult-to-treat cancer models.